Study of TPI 287 in Patients With Advanced Malignancies

Inclusion Criteria: * Histological or cytological evidence of malignancy * Patients must have either: * advanced solid tumors that have recurred or progressed following standard therapy, or * Hodgkin's or non-Hodgkin's lymphoma that has recurred or progressed following standard therapy, have not had a previous bone marrow transplant, and are not eligible for a bone marrow transplant. * Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy. * Ambulatory with ECOG 0 or 1, and a life expectancy of \>3 months. * Judged by the investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits. * Have ability to read, understand and provide written informed consent for the initiation of any study related procedures or have a legal representative to perform this function. * If female, must have a negative pregnancy test within 21 days of start of treatment. * Agree to the use of an effective method of contraception during the study and for 90 days following the last dose of medication. * Patients with prior radiation therapy for brain metastasis or primary brain tumors are acceptable. Exclusion Criteria: * Prior radiation therapy or chemotherapy within 4 weeks (6 weeks for prior nitrosoureas or mitomycin) * Another active medical condition(s) or organ disease(s) that may either compromise patient safety or interfere with the safety and/or outcome evaluation of the study drug. While this exclusion is not limited to the following abnormalities, if any of the following laboratory abnormalities are present, the patient should be excluded: * WBC \< 3000/uL; * Absolute neutrophil count \< 1500/uL; * Platelets \< 100,000/uL; * Total bilirubin \> 1.5 x upper limit of normal; * ALT or AST \> 3 x upper limit of normal if no liver metastases or \>5 upper limit of normal in the presence of liver metastases; * Serum creatinine \> 1.5 x upper limit of normal; * INR \>2.0. * Patient has clinically significant cardiac co-morbidities or pulmonary impairment * Patient or physician plans concomitant chemotherapy, radiation therapy, hormonal and/or biological treatment for cancer including immunotherapy while on study. Of note, therapy with LHRH for prostate cancer is acceptable. * Patient has been treated with any investigational drug, investigational biologic, or investigational therapeutic device within 30 days of initiating study treatment. * Tumor appears to involve a major artery or vein. * Prior or concurrent significant CNS disease including stroke, except for primary or secondary malignancies. * Less than 4 weeks since prior major surgery * Known positive for HIV, Hepatitis B or C * Concurrent chronic use of aspirin (325 mg/day or more) * Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters) Of note, therapy with low-molecular weight heparin is acceptable as long as the INR\<2.0. * Uncontrolled hypertension * Grade II-IV peripheral vascular disease within the past year * Prior allergic reactions to compounds of similar chemical or biologic composition to TPI 287, paclitaxel or taxotere, Cremophor-EL-P, or other study agents * Significant traumatic injury within the past 4 weeks * Ongoing or active infection requiring parenteral antibiotics or with a fever \>38.1°C within 3 days of the first scheduled day of dosing * Other concurrent uncontrolled illness which may interfere with the ability of the patient to participate in the trial * Patients who are inpatients * Grade II-IV peripheral neuropathy